Completed PHASE4 INTERVENTIONAL NCT00293696

Casodex/Zoladex Biomarkers in Localised Prostate Cancer

A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma

Sponsor: Tampere University

Conditions Prostate Cancer

Interventions bicalutamide (Casodex), goserelin (Zoladex)

Updated 7 times since 2017 Last updated: May 7, 2007 Started: Oct 31, 2004 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00293696, this PHASE4 trial focuses on Prostate Cancer and remains completed. Sponsored by Tampere University, it has been updated 7 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Apr 2019 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Apr 2019 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tampere University

Data source: Tampere University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tampere, Finland